Viral conjunctivitis is the inflammation of the conjunctiva of viral etiology.
Signs and symptoms include unilateral or bilateral eye redness, foreign body sensation and follicular conjunctival reaction.
It may be caused by adenovirus, herpes simplex or molluscum contagiosum.
Tabbara KF, Hyndiuk, RA. Infections of the eye. 2nd ed. Boston: Little, Brown and Company; 1996:453-470
Caparas VL, Dy-Liacco JU, Espiritu CG, et al. Handbook of cornea and external diseases: Cornea Club of the Philippines; 2000
Weisbecker CA, Fraunfelder FT, Tipperman R. Physicians' desk reference for ophthalmic medicines. Montvale: Medical Economics Company Inc; 2002
Rhee DJ, Pyfer MF. The Wills eye manual: office and emergency room diagnosis and treatment of eye disease. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1999:121-122
American Academy of Ophthalmology Preferred Practice Patterns Committee Cornea/External Disease Panel. Preferred practice pattern: conjunctivitis. San Francisco: American Academy of Ophthalmology; 2003
American Academy of Ophthalmology Preferred Practice Patterns Committee Cornea/External Disease Panel. Preferred practice pattern: conjunctivitis. San Francisco: American Academy of Ophthalmology. 2003
Jacobs DS. Conjunctivitis. UpToDate. http://www.uptodate.com/contents/conjunctivitis. 16 Oct 2012. Accessed 14 Feb 2014
American Academy of Ophthalmology Cornea/External Disease PPP Panel, Hoskins Center for Quality Eye Care. Conjunctivitis Summary Benchmark – 2013. ONE Network. http://one.aao.org/summary-benchmark-detail/conjunctivitis-summary-benchmark--october-2012. Oct 2013. Accessed 14 Feb 2014
Alfonso SA, Fawley JD, Lu XA. Conjunctivitis. Primary Care: Clinics in Office Practice. 2015 Sep;42(3):325-345. http://dx.doi.org/10.1016/j.pop.2015.05.001.
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.